Søgning på udtrykket 'evusheld' giver 13 resultater


Nyt fra tidsskrifterne [8] Aktuelle smitsomme sygdomme [5]

Nyt fra tidsskrifterne [8]

Journal of the American Medical Association
16.08.2022
People eligible for COVID-19 preexposure prophylaxis (PrEP) with the monoclonal antibody combination of tixagevimab and cilgavimab (Evusheld) should be treated every 6 months to maintain protection against infection, according to the recently revised Fact Sheet for Healthcare Providers.
Clinical Microbiology and Infection
31.07.2022
Immunocompromised patients have an increased risk of severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France.
Journal of the American Medical Association
26.07.2022
Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 monoclonal antibodies must be administered intravenously or subcutaneously.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
Journal of the American Medical Association
16.08.2022
People eligible for COVID-19 preexposure prophylaxis (PrEP) with the monoclonal antibody combination of tixagevimab and cilgavimab (Evusheld) should be treated every 6 months to maintain protection against infection, according to the recently revised Fact Sheet for Healthcare Providers.
Journal of the American Medical Association
26.07.2022
Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 monoclonal antibodies must be administered intravenously or subcutaneously.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.

Aktuelle smitsomme sygdomme [5]

Medscape Infectious Diseases
7.10.2022
Evusheld preexposure prophylaxis shows promise in protecting certain immunocompromised patients from severe COVID-19, Cleveland Clinic researchers report. .
Medscape Infectious Diseases
29.07.2022
The monoclonal antibody is an available, highly effective preventive medication for millions of immunocompromised people, yet many patients ― and even some doctors ― are unaware of it or are unable to get it. .
Medscape Infectious Diseases
9.05.2022
WebMD's Chief Medical Officer, John Whyte, MD, discusses the new FDA-authorized preventative drug for COVID-19 called Evusheld. .
Medscape Infectious Diseases
7.10.2022
Evusheld preexposure prophylaxis shows promise in protecting certain immunocompromised patients from severe COVID-19, Cleveland Clinic researchers report. .
Medscape Infectious Diseases
9.05.2022
WebMD's Chief Medical Officer, John Whyte, MD, discusses the new FDA-authorized preventative drug for COVID-19 called Evusheld. .

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2022 Dansk Selskab for Infektionsmedicin

CVR: 33634307

version: 2.11.0 ● PHP version 8.0.26 ● design: Christian Philip Fischer

Side indlæst på 0.652 s

Cookies og privatliv